Mutant IDH2 Inhibitors Targeting 2-Hydroxyglutarate Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mutant IDH2 enzymes in cancer cells exhibit a new ability to catalyze the NADPH-dependent reduction of α-ketoglutarate to R(−)-2-hydroxyglutarate, contributing to cancer formation and progression, necessitating the development of inhibitors to target this neoactivity.
Innovation Solution
Development of compounds with specific structural formulas that inhibit mutant IDH2 enzymes, particularly those with alpha hydroxyl neoactivity, including pharmaceutically acceptable salts or hydrates, which are designed to target and inhibit the aberrant activity of mutant IDH2 enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mutant IDH2 enzymes are left untreated, then cancer cells can utilize the aberrant alpha hydroxyl activity to produce 2-hydroxyglutarate, contributing to cancer formation and progression, but this creates harmful effects through accumulation of oncogenic metabolites
Solution Approach 1:
The patent identifies and exploits the aberrant alpha hydroxyl activity of mutant IDH2 enzymes as a therapeutic target. By designing inhibitors that specifically block this neoactivity, the harmful 2-hydroxyglutarate production is converted into a controllable parameter, transforming the disease mechanism into a treatable condition with measurable response markers
Solution Approach 2:
The patent modifies the enzymatic parameter of IDH2 by introducing specific inhibitors that change the kinetic parameters of the enzyme-substrate interaction. The inhibitors alter the catalytic efficiency and substrate affinity, thereby controlling the production of 2-hydroxyglutarate and restoring metabolic balance in cancer cells
2Reliability
If specific inhibitors are designed to target mutant IDH2 alpha hydroxyl activity, then therapeutic specificity is improved, but the complexity of compound structure and synthesis increases
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features that target the unique active site geometry of mutant IDH2 enzymes. The inhibitors contain specific functional groups and spatial arrangements that selectively interact with the aberrant alpha hydroxyl activity, achieving high specificity without requiring overly complex molecular structures
Solution Approach 2:
The patent segments the inhibitor design into modular components, where core structural elements provide binding affinity and peripheral groups provide specificity. This modular approach allows systematic optimization of inhibitor properties and simplifies the synthesis process by enabling stepwise construction of the molecular structure
3Adaptability or versatility
If wild-type IDH2 enzyme activity is maintained, then normal metabolic function is preserved, but the aberrant activity of mutant IDH2 cannot be selectively inhibited without affecting normal metabolism
Solution Approach 1:
The patent employs asymmetry in inhibitor design by creating molecules with chiral centers and asymmetric structural features that match the specific stereochemistry of the mutant IDH2 active site. This asymmetric approach enables selective binding to the mutant enzyme's aberrant activity while sparing the wild-type enzyme, as the wild-type active site has different geometric characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds effectively inhibit mutant IDH2 enzymes, potentially treating cancers characterized by elevated levels of 2-hydroxyglutarate by reducing its production, thereby addressing the progression and formation of cancer.
Implementation Method 1
mutant IDH2 enzymes in cancer cells exhibit a new ability to catalyze the NADPH-dependent reduction of α-ketoglutarate to R(−)-2-hydroxyglutarate
Implementation Method 2
catalyze the NADPH-dependent reduction of α-ketoglutarate to R(−)-2-hydroxyglutarate
Implementation Method 3
The described compounds effectively inhibit mutant IDH2 enzymes, potentially treating cancers characterized by elevated levels of 2-hydroxyglutarate by reducing its production
Data Source
AI summary
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.